122 related articles for article (PubMed ID: 19904804)
21. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
[TBL] [Abstract][Full Text] [Related]
22. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
William WN; Uyeki J; Johnson FM; Feng L; Peeples BO; Fossella FV; Karp DD; Blumenschein GR; Stewart DJ; Glisson BS
Cancer; 2010 May; 116(10):2409-15. PubMed ID: 20225329
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
[TBL] [Abstract][Full Text] [Related]
24. A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer.
Han JY; Lim KY; Yu SY; Yun T; Kim HT; Lee JS
Cancer; 2011 May; 117(10):2178-85. PubMed ID: 21523731
[TBL] [Abstract][Full Text] [Related]
25. Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer.
Noro R; Yoshimura A; Yamamoto K; Miyanaga A; Mizutani H; Minegishi Y; Seike M; Kubota K; Kosaihira S; Hino M; Ando M; Nomura K; Okano T; Kobayashi K; Uematsu K; Gemma A;
Anticancer Res; 2013 Mar; 33(3):1117-23. PubMed ID: 23482789
[TBL] [Abstract][Full Text] [Related]
26. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.
Satouchi M; Kotani Y; Shibata T; Ando M; Nakagawa K; Yamamoto N; Ichinose Y; Ohe Y; Nishio M; Hida T; Takeda K; Kimura T; Minato K; Yokoyama A; Atagi S; Fukuda H; Tamura T; Saijo N
J Clin Oncol; 2014 Apr; 32(12):1262-8. PubMed ID: 24638015
[TBL] [Abstract][Full Text] [Related]
27. Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Xenidis N; Kotsakis A; Kalykaki A; Christophyllakis Ch; Giassas S; Kentepozidis N; Polyzos A; Chelis L; Vardakis N; Vamvakas L; Georgoulias V; Kakolyris S
Lung Cancer; 2010 Jun; 68(3):450-4. PubMed ID: 19783319
[TBL] [Abstract][Full Text] [Related]
28. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial.
Oh IJ; Kim KS; Park CK; Kim YC; Lee KH; Jeong JH; Kim SY; Lee JE; Shin KC; Jang TW; Lee HK; Lee KY; Lee SY
BMC Cancer; 2016 Aug; 16(1):690. PubMed ID: 27566413
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
[TBL] [Abstract][Full Text] [Related]
31. Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.
Yoshimura A; Noro R; Miyanaga A; Mizutani H; Kosaihira S; Minegishi Y; Seike M; Hino M; Ando M; Nomura K; Okano T; Kobayashi K; Gemma A;
Anticancer Res; 2012 Oct; 32(10):4473-8. PubMed ID: 23060575
[TBL] [Abstract][Full Text] [Related]
32. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
Schneider BJ; Kalemkerian GP; Ramnath N; Kraut MJ; Wozniak AJ; Worden FP; Ruckdeschel JC; Zhang X; Chen W; Gadgeel SM
Clin Lung Cancer; 2010 Jul; 11(4):223-7. PubMed ID: 20630823
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of biweekly irinotecan and cisplatin for patients with extensive stage disease small cell lung cancer.
Bae SH; Ryoo HM; Do YR; Song HS; Kwon KY; Kim MK; Lee KH; Hyun MS; Lee WS; Hur IK; Baek JH; Park KU
Lung Cancer; 2008 Jan; 59(1):76-80. PubMed ID: 17767977
[TBL] [Abstract][Full Text] [Related]
35. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.
Jeong J; Cho BC; Sohn JH; Choi HJ; Kim SH; Lee YJ; Jung MK; Shin SJ; Park MS; Kim SK; Chang J; Kim JH
Lung Cancer; 2010 Oct; 70(1):77-81. PubMed ID: 20138389
[TBL] [Abstract][Full Text] [Related]
36. Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.
Pectasides D; Samantas E; Fountzilas G; Briasoulis E; Kosmidis P; Skarlos D; Dimopoulos MA; Kalofonos HP; Economopoulos T; Syrigos K
Lung Cancer; 2007 Dec; 58(3):355-61. PubMed ID: 17698241
[TBL] [Abstract][Full Text] [Related]
37. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of topotecan and cisplatin in patients with small cell lung cancer.
Ichinose Y; Seto T; Nishiwaki Y; Kiura K; Sakai H; Yokoyama A; Segawa Y; Ando M; Watanabe K
Jpn J Clin Oncol; 2011 Feb; 41(2):197-203. PubMed ID: 20937601
[TBL] [Abstract][Full Text] [Related]
39. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.
Lee DH; Kim SW; Suh C; Lee JS; Lee JH; Lee SJ; Ryoo BY; Park K; Kim JS; Heo DS; Kim NK
Ann Oncol; 2008 Jan; 19(1):123-7. PubMed ID: 17823384
[TBL] [Abstract][Full Text] [Related]
40. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Lara PN; Natale R; Crowley J; Lenz HJ; Redman MW; Carleton JE; Jett J; Langer CJ; Kuebler JP; Dakhil SR; Chansky K; Gandara DR
J Clin Oncol; 2009 May; 27(15):2530-5. PubMed ID: 19349543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
